01244 3D MEDICINES
Watchlist3D MEDICINES News
3D MEDICINES: (1) DISCLOSEABLE TRANSACTION INVESTMENT IN A FUND AND SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS; (2) SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2022 ANNUAL REPORT; AND (3) CLARIFICATION OF INFORMATION ON THE ANNOUNCEMENTS
3D MEDICINES: Interim Report 2023
Siludi Pharmaceuticals (1244.HK): Revenue increased 70%, betting on cancer vaccines
On August 25, 3D Pharmaceuticals (1244.HK) (hereinafter collectively referred to as “Siludy Pharmaceuticals”), an innovative pharmaceutical company focusing on cancer treatment and cancer vaccines, announced the company's results for the first half of 2023. After being selected B and included in the Hong Kong Stock Connect, Siludi Pharmaceutical successfully handed over an impressive questionnaire with a revenue increase of over 70%. However, on the second trading day after the results were released, the company's stock price also jumped more than 9% higher. So, what key information was revealed behind this report card? What are the highlights of Syludy Pharmaceutical in the future? Revenue increased by 70.3%, and losses narrowed. Judging from financial indicators, think
3D RESULTS (01244) Announces Interim Results of 353 Million Yuan, Revenue Increased 70.3% Year Over Year
3D RESULTS (01244) announced the results for the 6 months ended June 30, 2023,...
3D MEDICINES: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023
3D RESULTS (01244.HK) plans to hold a board meeting on August 25 to approve interim results
GLONGHUI (01244.HK) announced on August 15, 2023 (Friday) that the company will hold a board meeting on August 25, 2023 (Friday) to consider and approve (among others) the unaudited interim results and announcements of the company and its subsidiaries for the six months ended June 30, 2023, as well as the payment of interim dividends (if any).
3D MEDICINES: DATE OF BOARD MEETING
Siludi Pharmaceuticals (1244.HK) successfully completed allotment of shares, focusing on long-term value investment opportunities
Revenue increased 66.1% to 74.6% in the first half of the year
3D Medicines Raises HK$226.8 Million From Share Placement
3D Medicines (HKG:1244) has raised net proceeds of HK$226.8 million from the issuance of around 2.2 million placing shares to at least six investors procured by J.P. Morgan Securities at HK$108.00 api
3D TOWARDS: Abnormal stock price fluctuations I don't know any reason for the fluctuation
3D TOGETS (01244) announced that the stock price and trading volume of the company's shares fluctuated unusually on July 19 and July 20, 2023. After making all reasonable inquiries about the company in the relevant circumstances, the Board confirmed that it was unaware of any reason leading to changes in stock prices or trading volume, or any information requiring disclosure to avoid false markets in the company's securities or any insider information required to be disclosed under Section XIVA of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong. The Board also confirmed that the Group's business operations were maintained well and that the Group's business operations and finances were maintained
3D TOWARDS (01244.HK): The Group's business is operating well without knowing any reason for changes in stock prices or trading volume
On July 20, GLONGHUI (01244.HK) announced that the company's board of directors noticed unusual fluctuations in the stock price and trading volume of the company's shares on July 19 and July 20, 2023. After making all reasonable inquiries about the company in the relevant circumstances, the Board confirmed that it was unaware of any reason leading to changes in stock prices or trading volume, or any information requiring disclosure to avoid a false market in the company's securities or any insider information subject to disclosure under Section XIVA of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong. The Board also confirmed the Group's business operations
3D RESPONSES (01244) Responds to changes in stock prices: there is no change in fundamentals and I don't know the reason for any changes in stock prices
The Zhitong Finance App learned that as of the midday closing of trading on July 20, the stock price of 3D NETWORKS (01244) had dropped more than 28% to HK$70. In response to this, in response to changes in the company's stock price, 3D MEDICINES responded to Zhitong Finance by saying that the company's business condition is good, and there has been no change in fundamentals. The company has always taken drugs seriously and achieved target milestones; stock price trends are market behavior, and the company is unaware of any reason that causes changes in stock prices or trading volume. According to reports, 3D MEDICINES recently announced that it plans to place 2.15 million shares at an placement price of HK$108 per share
Changes in Hong Kong stocks | 3D REQUIREMENTS (01244) fell more than 26%. The company recently announced a net funding of HK$226 million to be allocated
The Zhitong Finance App learned that 3D MONETATION (01244) closed down 19% yesterday and fell more than 26% today. As of press release, it fell 25.97% to HK$72.25, with a turnover of HK$35.9961 million. According to the news, 3D MEDICINES recently announced that it plans to place 2.15 million shares at an placement price of HK$108 per share, which is about 12.90% off the closing price on July 13. The estimated net funding is about $226 million, mainly for planned clinical trials to evaluate envolizumab monotherapy, as well as for the construction of production facilities in Xuzhou, China, and
3D Medicines to Raise HK$232.2 Million From Share Placement
3D Medicines' (HKG:1244) is looking to raise around HK$232.2 million through the allotment of up to 2.2 million shares to at least six investors procured by J.P. Morgan Securities at HK$108 apiece. Th
Express News | 3D Medicines to Use Placement Proceeds for R&D, Business Expansion
Express News | 3D Medicines Seeks to Raise HK$226.2M in Net Proceeds From Share Placement
3D TOOLS (01244.HK) plans to place a total of 2.15 million shares for a total of HK$232.2 million
On July 14, 2023 (before trading time), GLONGHUB (01244.HK) announced that on July 14, 2023 (before trading time), the company signed an placement agreement with the exclusive overall coordinator and placement agent J.P. Morgan Chase. Based on this, the placement agent has agreed to act as the company's agent and do its best to encourage no less than six underwriters to subscribe for a total of 2.15 million shares at a price of HK$108.00 per share. The placement of shares is equivalent to approximately 0.84% of the company's current issued share capital and about 0.83% of the expanded issued share capital following the placement. The placement of shares will be subject to a general mandate
Changes in Hong Kong stocks | 3D RETURN (01244) reached a record high of nearly 4%, and revenue for the first half of the year is expected to increase 66.1% year on year to 74.6%
The Zhitong Finance App learned that 3D MONEY (01244) rose nearly 4% again in the afternoon, reaching a high of HK$115.7, a record high. As of press release, it rose 3.32% to HK$115.1, with a turnover of HK$645.082 million. According to the news, 3D MEDICINES announced that the group's total revenue for the first half of 2023 is expected to be around RMB 343.8-3614 million, an increase of 66.1% to 74.6% over the previous year. Gross profit is expected to be about 319 million to 335.8 million yuan, an increase of 66.1% to 74.6% over the previous year
3D MEDICINES Fa Yingxi expects total revenue of about 343.8 million to 361.4 million yuan in the first half of the year
3D TOOLS (01244) announced that the group's total revenue for the first half of 2023 is expected to be around RMB 343.8-361.4 million, an increase of 66.1% to 74.6% over the previous year. Gross profit is expected to be around 319 million to 335.8 million yuan, an increase of 66.1% to 74.6% over the previous year. According to the announcement, the increase in total revenue and gross profit was mainly due to a sharp increase in revenue and gross profit from the company's products (i.e. Envida). The company's gross margin for the first half of 2023 is expected to be about 92.9%, the same as the previous year.
[Company Yingxi] 3D PROFIT (01244) is expected to increase its medium-term profit by 66.1%-74.6% to RMB 344-361 million
3D RETURN (01244) issued a positive earnings forecast. The Group's total revenue for the six months ending June 30, 2023 is expected to be between RMB 344 million and RMB 361 million, up 66.1% to 74.6% from revenue of approximately RMB 207 million for the six months ending June 30, 2022. The Group's gross profit from sales for the six months ended June 30, 2023 is expected to be between RMB 319 million and RMB 336 million, an increase of 66 million yuan from approximately RMB 192 million in the six months ended June 30, 2022.